|
|
||||||||
Eur J Cardiothorac Surg 2000;17:743-746
© 2000 Elsevier Science NL
Cardiothoracic Surgical Unit, Papworth Hospital, Cambridge CB3 8RE, UK
Corresponding author. Tel.: +44-1480-830-541; fax: +44-1480-364-744
e-mail: sam.nashef{at}papworth-tr.anglox.nhs.uk
| Abstract |
|---|
|
|
|---|
Key Words: Emergency Cardiopulmonary bypass Cardiac surgery
| 1. Introduction |
|---|
|
|
|---|
| 2. Methods |
|---|
|
|
|---|
In-hospital data included patient demographics, peri-operative information and clinical outcome. Pre-operative risk stratification was carried out using the Parsonnet score [1]. Operative information from the database was supplemented by a retrospective review of individual patient case notes. Long-term follow-up was undertaken by telephone interview of the patient or the general practitioner. Functional ability was recorded using the New York Heart Association (NYHA) classification.
The chi-squared and Fisher's exact tests were used to compare nominal variables, and the MannWhitney test was used for continuous data. Stepwise regression analysis was undertaken with hospital survival as the dependent variable. Eight independent variables were evaluated: age, sex, Parsonnet score, intra-aortic balloon pump (IABP) use following primary procedure and crash-BOB, indication group (bleeding versus non-bleeding), need for further aortic cross-clamping and findings at crash-BOB (definite diagnosis versus no definite diagnosis). Data are expressed as mean±standard deviation. A P-value of less than 0.05 was regarded as statistically significant.
| 3. Results |
|---|
|
|
|---|
|
|
|
Crash-BOB patients required an average of 8 extra intensive care days and 2 extra ward days. The total cost of these resources was £164 900 (including theatre time, cardiopulmonary bypass (CPB) and IABP use; see Table 4). This was equivalent to £7170 per life saved.
|
| 4. Discussion |
|---|
|
|
|---|
Crash-BOB occurred infrequently and was associated with a 42% salvage rate at hospital discharge. We believe that this is a highly satisfactory outcome considering that all 55 patients would invariably have died without intervention. Although bleeders tended to do better than non-bleeders, this was not statistically significant. The surgical findings at crash-BOB had a greater clinical impact on the likelihood of hospital survival: all patients in whom no cause for clinical deterioration was found at crash-BOB eventually died. Conversely, the need for a second period of aortic cross-clamping did not preclude a good clinical outcome; indeed, the majority of these patients did well. Aortic cross-clamp requirement at crash-BOB was found to be a significant predictor of hospital survival. These observations suggest that the identification and correction of a surgical primary cause of clinical deterioration is crucial in predicting a successful outcome following crash-BOB.
Parsonnet score was lower in those that survived to hospital discharge, and was found to be a significant predictor of hospital survival, as may be expected. Of particular interest was the finding that time between primary surgery and crash-BOB did not influence survival.
In the 23 hospital survivors morbidity was low and long-term functional outcome was good, providing further justification for the clinical value of crash-BOB intervention.
A potential disadvantage of crash-BOB originates from concerns over the rising costs of medical intervention in the face of limited resources and increasing demand for cardiac surgical procedures. These issues pose a major challenge for individuals involved in the funding, management and delivery of healthcare. As a result, high-cost interventions such as crash-BOB should be closely evaluated. Whilst it was relatively easy in this study to determine the clinical outcome of crash-BOB, the assessment of its cost implications was more difficult. Inclusion of capital costs was felt to be an incorrect representation of the real costs of crash-BOB, because many of these resources were already in place. Thus, to include the cost of medical staff that were already on call, or building costs that had already been covered in the charge costs of non-emergency operations would have considerably increased the calculated costs of crash-BOB, without actually having been a true expense of the procedure. We therefore chose to use only the variable costs of items necessary for the performance of a crash-BOB operation. Using these items, the total cost of crash-BOB in the 55 patients was less than £165 000. In other words, the cost of crash-BOB per life saved was less than £7200, an amount similar to the charge costs of coronary revascularization in our institution. We believe that the favourable clinical outcome of crash-BOB justifies this cost.
In conclusion, crash-BOB occurred in 0.8% of cases and was associated with a survival to discharge of 42%, and a justifiable cost of only £7170 per life saved. Establishing an accurate diagnosis for the cause of clinical deterioration resulting in crash-BOB intervention was important, and the need for a further period of aortic cross-clamping did not preclude a favourable outcome.
| Footnotes |
|---|
| Appendix A Conference discussion |
|---|
|
|
|---|
Mr Birdi: All patients who die within 24 h of surgery in our institution have postmortem information. We don't have that postmortem information, but it's very interesting, and we will be collecting that in due course.
Dr Murtra: Right. Because early in the sessions, on the first day there was a very interesting paper that showed that, for instance, in one case the postoperative theory for cause of death was bleeding complications from the abdomen or intestinal complications.
Mr Birdi: Well, there were some intra-abdominal complications. But a lot of these complications were not recorded as bleeding complications, they were patients who had myocardial dysfunction as a result of acidosis. All the patients who were recorded as having bled, actually did bleed, and they bled into the pericardium. And there were various causes of bleeding from a distal anastomosis, a proximal anastomosis, bleeding from a dissected aorta, and so forth.
Dr H. Aebert (Regensburg, Germany): How did you go on bypass? Did you always open the chest in the operating room? Or did you, for example, sometimes use the femoral vessels or go on bypass in the intensive care unit?
Mr Birdi: All patients in this study had their sternum re-opened. Now, this was either performed in theatre, or in the intensive care unit or it was performed on the ward. We have done a separate audit of cardiac arrest, that is no-output cardiac arrest, in our institution, on the recovery ward, that is not the ITU and not in theatre, and the results of that audit are being analyzed. In this particular study, 14 patients either arrested or had life-threatening complications on the ward, all of whom went on to crash-BOB, and we were able to resuscitate and save six patients, all of whom are now alive and well. So in our institution we are looking at this in some more detail. We are just wondering whether a scoop-and-run policy for all patients on the ward who arrest and do not respond to immediate effective resuscitation should be transferred to our theatre, heparinized and placed onto bypass, so that an accurate diagnosis for the cause of their deterioration can be made. And it would be interesting to see what the results of this intervention would be.
Dr M. Turina (Zurich, Switzerland): It's very interesting information and encouraging. It parallels our experience. What is the proportion of IMA patients in this material? A very common occurrence, in spite of all claims to the contrary, with the IMA patient and the hypertrophied left ventricle, is that the patient might crash due to a drop in blood pressure or some arrhythmia in the hours after surgery. We have all observed such patients and it is very easy to treat them, especially with minimally invasive techniques, inserting an additional vein graft. This is really a low-risk procedure if the patient is not brain-damaged due to prolonged resuscitation. What was your proportion of patients with this particular disorder? And the second question is, why do you cross-clamp if you have a simple coronary problem on the distal anastomosis which nowadays can be very well fixed with the beating-heart technique?
Mr Birdi: It's very difficult to answer the second question because this is a retrospective study and I wasn't there at the time for a lot of these.
With respect to the first question, I presume you're talking about internal mammary artery spasm. And I don't know the exact figures. I have a list of all the patients in my wallet over there. I couldn't present it here because there are just so many numbers. But a considerable proportion of those suffered internal mammary artery spasm or what was believed to be internal mammary artery spasm. The majority of those were effectively dealt with in the first instance with revascularization. And this involved the use of a vein distally to the LAD. But not all of them survived to hospital discharge.
With respect to the second question, I agree with you entirely that one may wish to avoid an extra period of cross-clamping, put the patient on bypass, stabilize and deal with whatever complications you can deal with without rendering the heart ischaemic once more. But it's interesting also then to see that the results of this study don't actually suggest that cross-clamping was a deleterious mechanism to outcome. I think what would be more deleterious is not being able to make the accurate diagnosis as to the cause of the deterioration. But clearly this work needs to be looked at in more detail, perhaps as a prospective study.
Mr A. Anyanwu (Middlesex, UK): Can you tell me what proportion of patients that had a cardiac arrest in your unit actually went back on bypass?
Mr Birdi: If we're talking about cardiac arrest with no output, the only data I can give you at this present time is the 14 patients who were on the ward, some of whom suffered a no-output cardiac arrest, all of whom were put onto bypass, six of whom survived to hospital discharge. Now, in a year we would expect perhaps five patients per year on our recovery ward to have some form of no-output cardiac arrest. That's been the estimated figure. I don't know the exact number. So over this period of time you would expect there to be perhaps 25 or 27. Some of those patients presumably then were put onto bypass, but I can't tell you that for sure.
Mr Anyanwu: You don't have data on the patients that arrested but were not put on bypass?
Mr Birdi: Yes. But not in these data.
Mr Anyanwu: I think the problem is you've suggested that this is a more cost-effective means of treating cardiac arrest and you can't really say that unless you've got a comparative group. Because it might be that some of these 55 patients would have survived without going on bypass. A lot of patients that have bleeding and crash do not necessarily need cardiopulmonary bypass. And you can't really say, from a point of economics, that it's more cost-effective unless you directly make a comparison with patients who had a cardiac arrest in similar situations in which you used an alternative strategy.
Mr Birdi: I'm not sure whether you missed my conclusion slide, but in my conclusion I don't state that cardiac arrest will benefit from crash-BOB. My conclusion is the group of patients are a heterogeneous group; not all of them had no-output cardiac arrest, and some of them were bleeders. But in that group of patients, all of whom required some form of intervention to save their life, we found that the cost implications were justifiable.
What we are interested in at our institution is to look at specifically these patients that you are talking about, the patients who suffer no-output cardiac arrest. We don't have data for that. We don't know whether the cost implications of treating those patients is justified. And that is the sort of work that we would like to think about carrying out in our institution. So I'm sorry, no, my conclusion is not based on that group of patients but on the basis of the heterogeneous group of patients here who we believed would not have survived without some kind of aggressive intervention.
Mr Anyanwu: So you believe none of these patients would have survived if you hadn't gone on bypass?
Mr Birdi: No, undoubtedly, none of these patients would have survived without intervention.
Mr J.R.L. Hamilton (Newcastle-upon-Tyne, UK): How long does it take to get a bypass pump set up in your unit?
Mr Birdi: Well, the only limiting factor would be the perfusionist. And we believe that that is a limiting factor. And we'd be looking at something like 15 min before, or 20 min at the most, before he could arrive in the institution. And you've seen the time between surgery and crash-BOB intervention. I don't actually know what the timing was between arrest with no output and cardiopulmonary bypass. It would be interesting to see what that is. But clearly that is an issue. And in our institution at the present time we would probably only be able to do that as quickly as 3040 min.
Dr Murtra: I would like to ask you if in the group of bleeding patients, did you have any patients with cardiac rupture? Because in our experience, among these patients that bleed because of cardiac rupture, the results are terrible. Unfortunately, we have a lot of very old patients, and normally the cardiac rupture after mitral valve replacement is a really tough complication and most of these patients die, whatever you do.
Mr Birdi: None of the patients had cardiac rupture related to mitral valve surgery. I have a list, I wish I could have put on the board here, but the writing would have been too small for the people in the back to see clearly, but none of the patients were cardiac rupture.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |